Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07032129 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

Study acronym: BAH2573
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or GPRC5D or both sequentially in the treatment of Relapsed/ Refractory Multiple myeloma
Trial Details
NCT Number NCT07032129
Lead Sponsor Essen Biotech
Conditions
(from sponsor)		 Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma, Refractory
Related terms Autoimmune Diseases, Multiple Myeloma, Neoplasms, Plasma Cell
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov